The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for AstraZeneca’s ...

Pilatus Biosciences, a US biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and ...

Danish clinical-stage techbio, Evaxion, which is specializing in developing AI-Immunology powered vaccines, today provided a ...

US biotech Response Pharmaceuticals (Nasdaq: RSPN) has unveiled top-line Phase II results for its experimental obesity ...

Maryland, USA-based biotech MacroGenics announced that effective as of August 13, 2025, Eric Risser has been appointed ...

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...

Danish CNS specialist Lundbeck has reported revenue grew 14% at constant exchange rates (CER), plus 14% DKK, to 12,258 ...

China-based RNA therapeutics developer Ribopeutic has raised close to 100 million yuan ($13.9 million) in pre-A financing, ...

Shares of Israel-based Nasus Pharma rose 7.6% to $8.88 in after-hours activity yesterday after it announced the pricing of ...

Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately ...

Clustered regularly interspaced short palindromic repeats (CRISPR)-based therapeutics are rapidly gaining traction for the ...

US biotech Vedanta Biosciences has abandoned development of its ulcerative colitis candidate VE202 after the bacterial cocktail failed to outperform placebo in a mid-stage trial.